Ghrelin Is No Longer Able to Stimulate Growth Hormone Secretion in Patients with Cushing’s Syndrome but Instead Induces Exaggerated Corticotropin and Cortisol Responses

Growth and growth hormone (GH) secretion are blunted or severely impeded in chronic hypercortisolism and in patients with Cushing’s syndrome. A mechanistic explanation for the effect however has yet to be provided. On the other hand, several properties of ghrelin, a new peptide recently identified as the endogenous ligand of the GH secretagogue receptor, are still largely unknown. The two aims of this study were to observe whether ghrelin-mediated GH secretion was altered, and to characterize the corticotropin (ACTH) and cortisol response to this new stimulus in patients with Cushing’s disease. Ten patients with active Cushing’s disease (6 harboring microadenomas and 4 with macroadenomas) and 10 sex- and age-matched controls were studied. Ghrelin was administered at a dose of 1 µg/kg i.v. and GH, ACTH and cortisol analyzed in duplicate. In control women, ghrelin induced GH secretion to levels of 74.4 ± 12.8 µg/l, while chronic hypercortisolism severely reduced the ghrelin-mediated GH release in all patients with Cushing’s disease (peak values 17.7 ± 5.2 µg/l). The slightly, but significantly higher adiposity of patients vs. controls may have contributed to the effect, since a significant negative correlation (r = 0.639) was found between the amplitude of the GH peak and body mass index. In control women, ghrelin increased ACTH and cortisol levels, with peaks at 57.4 ± 19.0 ng/l and 162 ± 16 µg/l, respectively. This secretion was enhanced in Cushing’s syndrome patients, with ACTH and cortisol values of 380.7 ± 109.8 ng/l and 338 ± 81 µg/l respectively, both significantly higher than in controls. In conclusion, ghrelin-induced GH secretion was severely blunted in patients with active Cushing’s syndrome, in addition to a remarkable hyper-response in ACTH and cortisol secretion. These findings could have implications for the understanding of the physiology and physiopathology of interactions between GH and ACTH regulation.

[1]  F. Casanueva,et al.  Ghrelin: The Link Connecting Growth with Metabolism and Energy Homeostasis , 2002, Reviews in Endocrine and Metabolic Disorders.

[2]  M. Papotti,et al.  The GH‐releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans , 2002, Clinical endocrinology.

[3]  K. Hosoda,et al.  Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[4]  B. Wisse,et al.  A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. , 2001, Diabetes.

[5]  M. Tschöp,et al.  Post-prandial decrease of circulating human ghrelin levels , 2001, Journal of endocrinological investigation.

[6]  M. Papotti,et al.  Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. , 2001, The Journal of clinical endocrinology and metabolism.

[7]  K. Toshinai,et al.  Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. , 2001, Biochemical and biophysical research communications.

[8]  M. Papotti,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatura , 2022 .

[9]  K. Nakao,et al.  Ghrelin strongly stimulates growth hormone release in humans. , 2000, The Journal of clinical endocrinology and metabolism.

[10]  F. Casanueva,et al.  Ghrelin-induced growth hormone secretion in humans. , 2000, European journal of endocrinology.

[11]  R. Pasquali,et al.  Abnormalities of the hypothalamic-pituitary-adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration. , 2000, The Journal of clinical endocrinology and metabolism.

[12]  S. Dickson,et al.  Systemic Administration of Ghrelin Induces Fos and Egr‐1 Proteins in the Hypothalamic Arcuate Nucleus of Fasted and Fed Rats , 2000, Journal of neuroendocrinology.

[13]  F. Casanueva,et al.  Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats. , 2000, European journal of endocrinology.

[14]  M. Papotti,et al.  Growth hormone secretagogue binding sites in peripheral human tissues. , 2000, The Journal of clinical endocrinology and metabolism.

[15]  F. Casanueva,et al.  GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults , 2000, The Lancet.

[16]  M. Papotti,et al.  Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans , 2000, Journal of endocrinological investigation.

[17]  M. Nakazato,et al.  Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. , 2000, Biochemical and biophysical research communications.

[18]  F. Casanueva,et al.  Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation. , 2000, European journal of endocrinology.

[19]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[20]  M. Korbonits,et al.  The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. , 1999, The Journal of clinical endocrinology and metabolism.

[21]  F. Casanueva,et al.  Growth Hormone Secretagogues: Physiological Role and Clinical Utility , 1999, Trends in Endocrinology & Metabolism.

[22]  J. Veldhuis,et al.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. , 1998, Endocrine reviews.

[23]  G. Arnaldi,et al.  Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. , 1998, The Journal of clinical endocrinology and metabolism.

[24]  F. Casanueva,et al.  Interaction between body composition, leptin and growth hormone status. , 1998, Bailliere's clinical endocrinology and metabolism.

[25]  D. Schoenfeld,et al.  Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. , 1998, The Journal of clinical endocrinology and metabolism.

[26]  M. Buysschaert,et al.  Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas. , 1998, European journal of endocrinology.

[27]  Jimenez,et al.  Enhanced growth hormone (GH) responsiveness to GH‐releasing hormone after dietary restriction in patients with Cushing's syndrome , 1998, Clinical endocrinology.

[28]  X. Bertagna,et al.  Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors. , 1997, European journal of endocrinology.

[29]  F. Casanueva,et al.  Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome. , 1997, The Journal of clinical endocrinology and metabolism.

[30]  E. Arvat,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Adrenocorticotropin- and Cortisol-Releasing Effect of Hexarelin, a Synthetic Growth Hormone-Releasing , 2022 .

[31]  T. Yoshimoto,et al.  Clinico‐pathological study of Cushing's disease with large pituitary adenoma , 1997, Clinical endocrinology.

[32]  H. Orskov,et al.  Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. , 1997, The American journal of physiology.

[33]  I. Robinson,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Activation of the Hypothalamo-Pituitary-Adrenal Axis by the Growth Hormone (GH) Secretagogue, GH-Releasing Peptide-6, in Rats , 2022 .

[34]  Patrick R. Griffin,et al.  A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.

[35]  R. Mcdowell,et al.  In vitro characterization of four novel classes of growth hormone-releasing peptide. , 1995, Endocrinology.

[36]  B. Imbimbo,et al.  Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. , 1995, The Journal of endocrinology.

[37]  F. Casanueva,et al.  Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. , 1995, The Journal of clinical endocrinology and metabolism.

[38]  F. Casanueva,et al.  Influence of metabolic substrates and obesity on growth hormone secretion , 1995, Trends in Endocrinology & Metabolism.

[39]  H. de Boer,et al.  Clinical aspects of growth hormone deficiency in adults. , 1995, Endocrine reviews.

[40]  F. Casanueva,et al.  Inhibition of growth hormone release after the combined administration of CHRH and GHRP‐6 in patients with Cushing's syndrome , 1994, Clinical endocrinology.

[41]  F. Casanueva,et al.  Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. , 1993, The Journal of clinical endocrinology and metabolism.

[42]  F. Casanueva,et al.  Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome , 1993, Clinical endocrinology.

[43]  F. Cordido,et al.  EFFECT OF ENHANCEMENT OF ENDOGENOUS CHOLINERGIC TONE WITH PYRIDOSTIGMINE ON GROWTH HORMONE (GH) RESPONSES TO GH‐RELEASING HORMONE IN PATIENTS WITH CUSHING'S SYNDROME , 1990, Clinical endocrinology.

[44]  P. Sönksen,et al.  The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. , 1989, The New England journal of medicine.

[45]  N. Skakkebaek,et al.  BENEFICIAL EFFECTS OF GROWTH HORMONE TREATMENT IN GH-DEFICIENT ADULTS , 1989, The Lancet.

[46]  T. Benraad,et al.  HUMAN PANCREATIC GROWTH HORMONE RELEASING HORMONE FAILS TO STIMULATE HUMAN GROWTH HORMONE BOTH IN CUSHING'S DISEASE AND IN CUSHING'S SYNDROME DUE TO ADRENOCORTICAL ADENOMA , 1986, Clinical endocrinology.

[47]  F. Momany,et al.  On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. , 1984, Endocrinology.

[48]  H. Demura,et al.  Responses of plasma ACTH, GH, LH and 11-hydroxycorticosteroids to various stimuli in patients with Cushing's syndrome. , 1972, The Journal of clinical endocrinology and metabolism.

[49]  G. Chrousos,et al.  Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure. , 1994, The Journal of clinical endocrinology and metabolism.

[50]  A. Iranmanesh,et al.  Divergent effects of short term glucocorticoid excess on the gonadotropic and somatotropic axes in normal men. , 1992, The Journal of clinical endocrinology and metabolism.

[51]  B. Burguera,et al.  Acute administration of corticoids: a new and peculiar stimulus of growth hormone secretion in man. , 1990, The Journal of clinical endocrinology and metabolism.